Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
I2o Therapeutics Inc.
Headquarters: Allston, MA, United States of America
Website: https://www.i2obio.com/
Year Founded: 2019
Status: Private
BioCentury | Aug 3, 2024
Deals
Biotechs find problem-solving in academia, and mostly outside the big hubs
Academia-biotech deals span innovative assets to tissue bank resources to enabling technologies
BioCentury | Sep 21, 2023
Regulation
Another setback for implantable GLP-1 as FDA panel cites safety, delivery concerns
Even if ITCA 650 were approved, the diabetes therapy would have a tough commercial road
BioCentury | Aug 31, 2023
Data Byte
Public hearing in September for implantable diabetes therapy
Committees to also discuss sNDA for Onpattro and BLA for NurOwn
BioCentury | Aug 28, 2023
Management Tracks
Kurt Graves takes top spot at i2o
Plus: Lourie Zak becomes CFO at Genelux, and updates from Delve Bio, Leo, and Synthetica
BioCentury | Oct 15, 2021
Management Tracks
Malek joins NIBR as head of oncology disease area
Plus: Translate Bio vet Smith joins CRISPR as CFO and updates from Travere, Kojin, AMO, Poseida, Synairgen and more
BioCentury | Feb 12, 2021
Deals
Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta
Shares of Bioventus Inc. (NASDAQ:BVS) rose 48% to $19.21 in its first day of trading after raising $104 million in an IPO through the sale of 8 million shares at $13. $80M series C for Versant-grown
BioCentury | Apr 15, 2020
Finance
April 14 Quick Takes: Digital Dx play Perspectum raises $36M; plus Akeso’s IPO terms, 54gene, i2O and Immunovant
Items per page:
1 - 7 of 7